NAGE
Niagen Bioscience, Inc.
NASDAQ: NAGE · CONSUMER DEFENSIVE · PACKAGED FOODS
$3.04
+0.16% today
Updated 2026-09-11
Market cap
$240.15M
P/E ratio
15.97
P/S ratio
1.86x
EPS (TTM)
$0.19
Dividend yield
—
52W range
$3 – $11
Volume
0.6M
WallStSmart proprietary scores
40
out of 100
Grade: D
Sell
Investment rating
4.7
Growth
C8.5
Quality
A6.0
Profitability
B6.0
Valuation
B4/9
Piotroski F-Score
Moderate
2.0
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$12.08
+297.37%
12-Month target
$3.62
+19.08%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 22.64% — strong efficiency
+ Free cash flow $2.68M — positive
+ Debt/equity 0.03x — low leverage
Risks
- Revenue declining -4.30% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $72.05M | $83.57M | $99.60M | $129.42M | $129.08M |
| Net income | $-16.54M | $-4.94M | $8.55M | $17.38M | $963000.00 |
| EPS | — | — | — | — | $0.19 |
| Free cash flow | $-15.43M | $6.97M | $11.95M | $13.14M | $2.68M |
| Profit margin | -22.96% | -5.91% | 8.58% | 13.43% | 12.40% |
Peer comparison
Smart narrative
Niagen Bioscience, Inc. trades at $3.04. representing a P/E of 15.97x trailing earnings. Our Smart Value Score of 40/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.02, it sits in the grey zone. TTM revenue stands at $129.08M. with profit margins at 12.40%.
Frequently asked questions
What is Niagen Bioscience, Inc.'s stock price?
Niagen Bioscience, Inc. (NAGE) trades at $3.04, on a P/E of 16.0x and a P/S of 1.9x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Niagen Bioscience, Inc. overvalued?
Niagen Bioscience, Inc. carries a Smart Value Score of 40/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Niagen Bioscience, Inc. (NAGE)?
The 12-month analyst consensus target is $12.08, about 297.4% above the current $3.04. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Niagen Bioscience, Inc.'s revenue?
Niagen Bioscience, Inc.'s trailing twelve-month revenue is $129.08M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Niagen Bioscience, Inc.'s Altman Z-Score is 2.02, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorCONSUMER DEFENSIVE
IndustryPACKAGED FOODS
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.86x
ROE22.64%
Beta2.09
50D MA$3.25
200D MA$4.62
Shares out0.08B
Float0.06B
Short ratio—
Avg volume0.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—